Candriam S.C.A. Jounce Therapeutics, Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$6.01 - $8.54 $2.03 Million - $2.88 Million	-337,398 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$6.58 - $10.66 $2.22 Million - $3.6 Million	337,393 Added 6747860.0%	337,398 $2.29 Million
Q1 2021 Apr 29, 2021	BUY	$6.73 - $13.87 $33 - $69	5 New	5 $0
Q4 2020 Jan 22, 2021	SELL	$6.37 - $10.33 $2.25 Million - $3.64 Million	-352,760 Closed	0 $0
Q3 2020 Oct 19, 2020	BUY	$4.58 - $10.95 $1.62 Million - $3.86 Million	352,760 New	352,760 $2.88 Million
Q3 2018 Nov 07, 2018	SELL	$6.5 - $8.37 $162,500 - $209,249	-25,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $181,750 - $547,000	25,000 New	25,000 $192,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.